Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report)'s stock price traded up 6.6% during mid-day trading on Monday . The stock traded as high as $13.41 and last traded at $13.58. 210,561 shares were traded during mid-day trading, a decline of 80% from the average session volume of 1,076,501 shares. The stock had previously closed at $12.74.
Analysts Set New Price Targets
DNLI has been the subject of several recent research reports. JPMorgan Chase & Co. decreased their price objective on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a report on Tuesday, January 7th. B. Riley restated a "buy" rating and set a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. William Blair restated an "outperform" rating on shares of Denali Therapeutics in a report on Friday, February 28th. Bank of America reduced their price objective on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a report on Monday, March 10th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 target price for the company. One equities research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $37.57.
Read Our Latest Stock Analysis on Denali Therapeutics
Denali Therapeutics Price Performance
The stock has a fifty day moving average of $15.09 and a 200 day moving average of $20.94. The firm has a market capitalization of $2.22 billion, a P/E ratio of -5.57 and a beta of 1.58.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. Equities analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC lifted its stake in Denali Therapeutics by 101.4% in the third quarter. Barclays PLC now owns 255,883 shares of the company's stock valued at $7,454,000 after purchasing an additional 128,823 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Denali Therapeutics by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 80,041 shares of the company's stock valued at $2,148,000 after buying an additional 2,901 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after acquiring an additional 149,939 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Denali Therapeutics by 6.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock worth $6,857,000 after acquiring an additional 14,324 shares during the period. Finally, SG Americas Securities LLC increased its holdings in Denali Therapeutics by 128.8% in the 4th quarter. SG Americas Securities LLC now owns 11,003 shares of the company's stock worth $224,000 after acquiring an additional 6,195 shares during the last quarter. 92.92% of the stock is owned by institutional investors.
Denali Therapeutics Company Profile
(
Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
See Also
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
